

Dr. Kusum lata

Prachi

Document Details

Submission ID

trn:oid:::27535:139423452

Submission Date

May 18, 2026, 9:26 AM GMT+0

Download Date

May 18, 2026, 9:29 AM GMT+0

File Name

Prachi.pdf

File Size

780.7 KB

49 Pages

11,794 Words

68,794 Characters

10% Overall Similarity

The combined total of all matches, including overlapping sources, for each database.

Filtered from the Report

- Bibliography
- Quoted Text
- Small Matches (less than 8 words)

Match Groups

-  **86 Not Cited or Quoted 10%**
Matches with neither in-text citation nor quotation marks
-  **3 Missing Quotations 0%**
Matches that are still very similar to source material
-  **0 Missing Citation 0%**
Matches that have quotation marks, but no in-text citation
-  **0 Cited and Quoted 0%**
Matches with in-text citation present, but no quotation marks

Top Sources

- 8%  Internet sources
- 4%  Publications
- 8%  Submitted works (Student Papers)

Integrity Flags

0 Integrity Flags for Review

Our system's algorithms look deeply at a document for any inconsistencies that would set it apart from a normal submission. If we notice something strange, we flag it for you to review.

A Flag is not necessarily an indicator of a problem. However, we'd recommend you focus your attention there for further review.

Match Groups

- 86 Not Cited or Quoted 10%**
Matches with neither in-text citation nor quotation marks
- 3 Missing Quotations 0%**
Matches that are still very similar to source material
- 0 Missing Citation 0%**
Matches that have quotation marks, but no in-text citation
- 0 Cited and Quoted 0%**
Matches with in-text citation present, but no quotation marks

Top Sources

- 8% Internet sources
- 4% Publications
- 8% Submitted works (Student Papers)

Top Sources

The sources with the highest number of matches within the submission. Overlapping sources will not be displayed.

1	Internet	dspace.dtu.ac.in:8080	1%
2	Internet	www.coursehero.com	<1%
3	Internet	dspace.kuet.ac.bd	<1%
4	Internet	su-plus.strathmore.edu	<1%
5	Internet	oregonstate.edu	<1%
6	Internet	repository.iaa.ac.tz:8080	<1%
7	Internet	ijsrem.com	<1%
8	Student papers	BB9.1 PROD on 2026-04-24	<1%
9	Internet	r4r4w9g2.rocketcdn.me	<1%
10	Internet	irbackend.mubs.ac.ug	<1%

11	Student papers	Galileo Global Education on 2026-05-01	<1%
12	Internet	www.mdpi.com	<1%
13	Student papers	Botswana International University of Science and Technology on 2026-05-08	<1%
14	Publication	Nesamvuni, Philelo. "The Business Performance of Small-Scale Tomato Farmers i...	<1%
15	Internet	www.nexteraenergycanada.com	<1%
16	Student papers	Aston University on 2026-03-26	<1%
17	Student papers	Islington College,Nepal on 2026-05-15	<1%
18	Student papers	La Sagesse University on 2016-02-17	<1%
19	Internet	bsum.edu.ng	<1%
20	Student papers	Aston University on 2013-03-14	<1%
21	Internet	scholar.lib.vt.edu	<1%
22	Internet	ajnpp.umsha.ac.ir	<1%
23	Publication	Akindutire, Adekemi. "Effects of Purpose Alignment on Affective Commitment, Co...	<1%
24	Student papers	Alliance Ascent College on 2026-05-07	<1%

25	Student papers	Herzing University on 2025-11-24	<1%
26	Internet	dspace.unza.zm	<1%
27	Internet	repository.ntu.edu.sg	<1%
28	Student papers	King Abdulaziz University - Scientific Research on 2025-12-28	<1%
29	Internet	pdfs.semanticscholar.org	<1%
30	Internet	africadailynews.net	<1%
31	Internet	e-research.siam.edu	<1%
32	Internet	www.ijmh.org	<1%
33	Student papers	York St John University on 2025-09-11	<1%
34	Internet	etd.uum.edu.my	<1%
35	Internet	mbsresearch.com	<1%
36	Internet	www.inderscience.com	<1%
37	Internet	www.livemint.com	<1%
38	Student papers	College Faculty Members on 2026-05-08	<1%

39	Publication	Tallia, Jim . "Effect of Sales Call Rate Controls on Industrial Sales Performance.", U...	<1%
40	Student papers	University of Wales Institute, Cardiff on 2026-04-23	<1%
41	Internet	archive.org	<1%
42	Internet	digitalcollection.utem.edu.my	<1%
43	Internet	psychologyandeducation.net	<1%
44	Internet	www.ijprems.com	<1%
45	Internet	www.preprints.org	<1%
46	Internet	www.printspublications.com	<1%
47	Student papers	Alliance University on 2026-05-05	<1%
48	Student papers	Delhi Technological University on 2019-03-08	<1%
49	Student papers	Dublin Business School on 2026-01-07	<1%
50	Student papers	University of Leicester on 2010-09-08	<1%
51	Student papers	University of Northumbria at Newcastle on 2014-12-18	<1%
52	Internet	eprints.hud.ac.uk	<1%

53	Internet	ttu-ir.tdl.org	<1%
54	Internet	www.doversociety.org.uk	<1%
55	Internet	www.iaraedu.com	<1%
56	Student papers	Alliance Ascent College on 2026-05-07	<1%
57	Student papers	Buckinghamshire Chilterns University College on 2025-12-15	<1%
58	Student papers	CEG Digital and UCLan university on 2024-08-25	<1%
59	Student papers	CSU, Long Beach on 2006-02-13	<1%
60	Student papers	Glasgow Caledonian University on 2026-04-17	<1%
61	Publication	Mitra, Dipa. "The Impact of Mentors' Adaptive Leadership Style and Mentees' Em...	<1%
62	Student papers	University of Stellenbosch, South Africa on 2011-11-18	<1%
63	Internet	cuts-ccier.org	<1%
64	Internet	merimaxpub.org	<1%
65	Internet	openresearch-repository.anu.edu.au	<1%
66	Internet	thesis.eur.nl	<1%

67

Internet

www.dspace.dtu.ac.in:8080

<1%

68

Internet

www.econstor.eu

<1%

Project Dissertation Report on

From Coverage to Conversion: MR Allocation and Prescription Uptake in Tier 2 India

Submitted By

Prachi

MBA Business Analytics, Semester IV

Roll No.: 24/BMBA/25

Under the Guidance of

Dr. Kusum Lata

Assistant Professor



DELHI SCHOOL OF MANAGEMENT

Delhi Technological University

Bawana Road, Delhi 110042

Academic Year 2025 to 2026

CERTIFICATE

This is to certify that the Project Dissertation Report entitled: "**From Coverage to Conversion: MR Allocation and Prescription Uptake in Tier 2 India**" has been submitted by Ms. Prachi, MBA Business Analytics, Semester IV, in partial fulfilment of the requirements for the degree of Master of Business Administration at Delhi School of Management, Delhi Technological University.

This work is the bonafide work of the student and has been carried out under my supervision and guidance. To the best of my knowledge, the report is original and has not been submitted elsewhere for any degree or diploma.

Signature

Dr. Kusum Lata

Assistant Professor

Delhi School of Management

Delhi Technological University

Date: 19 May 2026

Place: New Delhi

DECLARATION

I, Prachi, student of MBA Business Analytics Semester IV, Delhi School of Management Delhi Technological University hereby declare that the Project Dissertation Report entitled: **"From Coverage to Conversion: Medical Representative Allocation and Prescription Uptake in Tier 2 India"** submitted in fulfilment of the requirements for the degree of Master of Business Administration is my original work. The report has not been submitted for any degree or diploma at this or any other institution. All sources of information used in this report have been duly acknowledged.

I further declare that the plagiarism in this report is than 20 percent as required by the Delhi Technological University guidelines.

Prachi

Roll No.: 24/BMBA/25

MBA Business Analytics, Semester IV

Delhi School of Management, DTU

Date: 19 May 2026

Place: New Delhi

ACKNOWLEDGEMENT

I want to thank everyone who helped me finish this dissertation project.

I am really thankful to my guide Dr. Kusum Lata, Assistant Professor, Delhi School of Management Delhi Technological University for guiding me and giving me feedback throughout the research process.

I thank the faculty of Delhi School of Management for teaching me the skills I needed to do this research. The courses I took in Business Analytics, Marketing Management and Research Methodology gave me the knowledge I used in this study.

I am grateful to the doctors and general physicians in Indore, Jaipur and Lucknow who took the time to answer my survey questions. Their answers were really important for this research.

I also thank the organisations and publications including IQVIA, the AIOCD Awacs panel, the Ministry of Health and Family Welfare and Statista for making industry data available through reports and databases.

Finally I thank my family and friends for supporting me throughout my journey.

Prachi

Roll No.: 24/BMBA/25

MBA Business Analytics, Semester IV

Delhi School of Management, DTU

EXECUTIVE SUMMARY

India's pharmaceutical industry is really big. Is expected to reach USD 130 billion by 2030. While big cities have always been the focus of pharmaceutical marketing Tier 2 cities like Indore, Jaipur and Lucknow, are growing fast. They have people with money, better healthcare and more chronic diseases.. The way medical representatives are allocated in these cities is not well planned.

This dissertation looked at how medical representatives are allocated how they cover their territories and how this affects prescription uptake in Tier 2 Indian pharmaceutical markets. I used a mixed-method research design that combined survey data and industry analysis. I surveyed 118 practitioners and physicians in Indore, Jaipur and Lucknow. I also used data from IQVIA, AIOCD Awacs and other sources.

The study found that medical representative visit frequency is positively correlated with prescription volume. Territory coverage is the predictor of conversion rate. There are differences in prescription conversion rates across the three cities. Lucknow had the conversion rate while Jaipur had the lowest.

Based on these findings I recommend that pharmaceutical companies use a frequency-weighted territory allocation model provide relationship intensity training for representatives and use AIOCD prescription audit data to reallocate territories.

This study shows that medical representative allocation strategy can improve prescription conversion in -metro Indian pharmaceutical markets.

TABLE OF CONTENTS

Certificate	i
Declaration	ii
Acknowledgement	iii
Executive Summary	iv
Table of Contents	v
List of Tables	vii
List of Figures.....	viii
Chapter 1: Introduction	1
1.1 Background	1
1.2 Problem Statement	2
1.3 Objectives of the Study	3
1.4 Scope of the Study	4
1.5 Significance of the Study	4
1.6 Overview of Research Tools and Data	5
1.7 Organisation of the Report.....	6
Chapter 2: Literature Review	7
2.1 MR Detailing and Prescription Influence	7
2.2 Territory Allocation in Pharma Sales	7
2.3 Tier 2 Market Dynamics in Indian Pharma.....	8
2.4 Doctor-MR Relationship Quality and Prescribing Behaviour	8
2.5 Reach and Frequency Models in Pharma Marketing.....	9
2.6 Research Gap	9
Chapter 3: Research Methodology	10
3.1 Research Design	10
3.2 Data Sources and Collection.....	10
3.3 Sampling Design and Sample Size Justification.....	11
3.4 Questionnaire Design.....	12

3.5	Analytical Methods and Statistical Techniques.....	13
3.6	Reliability and Validity.....	14
3.7	Ethical Considerations	15
3.8	Limitations of Methodology	15
Chapter 4:	Analysis, Discussion and Recommendations	16
4.1	Introduction to the Analysis.....	16
4.2	Secondary Data Analysis: Indian Pharma Market and Tier 2 Landscape	16
4.3	Descriptive Analysis of Primary Data	18
4.4	MR Visit Frequency and Prescription Influence Analysis	19
4.5	Territory Coverage and Conversion Analysis	20
4.6	City-wise Comparative Analysis	21
4.7	Correlation and Regression Analysis.....	23
4.8	Reliability Analysis (Cronbach Alpha).....	26
4.9	Discussion of Findings.....	27
4.10	Recommendations.....	28
4.11	Limitations of the Study	30
Chapter 5:	Conclusion.....	31
References.....		34
Annexure A:	Questionnaire	36
Annexure B:	Sample Data Extract.....	40

LIST OF TABLES

Table 1.1	Study Overview: Key Parameters and Research Scope.....	2
Table 1.2	Target Cities: Profile and Rationale for Selection	5
Table 3.1	Data Sources and Parameters Collected	11
Table 3.2	Sample Distribution across Three Cities	12
Table 3.3	Questionnaire Structure and Construct Mapping	13
Table 3.4	Statistical Techniques and their Application	14
Table 4.1	India Pharma Market Size and Tier 2 Share (2019 to 2024)	16
Table 4.2	MR-to-Doctor Ratio: Metro vs Tier 2 Markets	17
Table 4.3	Respondent Profile by City, Specialisation, and Experience	18
Table 4.4	Descriptive Statistics: MR Visit Frequency and Prescription Volume	19
Table 4.5	MR Visit Frequency Category-wise Average Prescription Conversion Rate	19
Table 4.6	Territory Coverage Index by City.....	21
Table 4.7	City-wise Comparative Summary: Coverage, Frequency, Conversion....	22
Table 4.8	Pearson Correlation Matrix: Key Study Variables	23
Table 4.9	Regression Analysis Output: Predictors of Prescription Conversion	24
Table 4.10	ANOVA Results: Prescription Conversion Rate across Three Cities	25
Table 4.11	Cronbach Alpha Reliability Scores by Construct	26
Table 4.12	Summary of Key Findings and Managerial Implications.....	28
Table 4.13	Recommended Frequency-Weighted Territory Allocation Model.....	29
Table 5.1	Summary of Research Objectives and Corresponding Findings	32
Table A1	Sample Extract from Primary Survey Dataset	40

LIST OF FIGURES

Figure 4.1 MR Visit Frequency vs Average Prescription Conversion Rate (Bar Chart)	20
Figure 4.2 Territory Coverage Index by City (Clustered Bar Chart).....	21
Figure 4.3 City-wise Conversion Rate Comparison: Indore, Jaipur, Lucknow	22
Figure 4.4 Scatter Plot: MR Visit Frequency vs Prescription Influence Score	23
Figure 4.5 Regression Output: Predicted vs Actual Prescription Influence Score ...	25

CHAPTER 1

INTRODUCTION

1.1 Background

The Indian pharmaceutical industry is very important in the healthcare system. India is the world's largest pharmaceutical market by volume and the largest supplier of generic medicines globally. In 2023 India accounted for 20 percent of global generic drug exports by volume. The domestic market in India was valued at USD 50 billion in 2023 and has been growing at a rate of 9 to 11 percent every year. This growth is driven by people becoming more aware of their health, more people having health insurance and the increasing number of people with -communicable diseases like diabetes and heart problems.

In the past Indian pharmaceutical companies focused on cities like Mumbai, Delhi and Bengaluru. These cities have a lot of specialist doctors, big hospitals and people who can afford to buy medicines. Now smaller cities like Indore, Jaipur and Lucknow are growing fast. These cities have healthcare facilities, more money to spend and a growing demand for medicines.

The medical representative is the person who connects a pharmaceutical company with doctors in India. Unlike in countries, where digital marketing and advertising are big, the Indian pharmaceutical market relies heavily on personal relationships. Medical representatives visit doctors to give them information about medicines, distribute samples and build relationships with them. According to a report by IQVIA, there were 650,000 medical representatives in India in 2023.

Despite the importance of representatives, there is not much research on how they affect the sales of medicines in smaller cities. Most research has been done in countries, where the market is different. In India, research has focused on cities, leaving smaller cities like Indore, Jaipur and Lucknow understudied. This lack of research means that pharmaceutical companies do not have the information they need to make

decisions about where to send their medical representatives and how to cover their territories.

This study looked at the relationship between medical representative allocation, territory coverage and the sales of medicines in three cities: Indore, Jaipur and Lucknow. The study used a mix of secondary data including a survey of 118 doctors and analysis of industry data.

Table 1.1 Study Overview: Key Parameters and Research Scope

Parameter	Details
Title	From Coverage to Conversion: MR Allocation and Prescription Uptake in Tier 2 India
Research Design	Mixed Method (Primary Survey + Secondary Data Analysis)
Study Geography	Indore (MP), Jaipur (Rajasthan), Lucknow (UP)
Primary Sample Size	118 valid responses (GPs and Physicians)
Data Collection Tool	Structured questionnaire (5-point Likert scale)
Secondary Data Sources	IQVIA, AIOCD Awacs, Ministry of Health, Statista, Company Annual Reports
Statistical Techniques	Descriptive Analysis, Pearson Correlation, Regression, ANOVA, Cronbach Alpha
Visualisation Tool	Microsoft Power BI
Study Period	January 2026 to April 2026

Source: Own analysis

1.2 Problem Statement

Indian pharmaceutical companies face a big challenge in smaller cities. They need to make sure their medical representatives are effective and cover all the doctors in their territories.. They do not have the information they need to make good decisions about where to send their medical representatives and how to configure their territories.

The current way of allocating representatives is based on convenience past sales data and the judgment of managers. This approach has some weaknesses. It does not take into account the differences in doctor density prescribing volume and therapeutic

segment relevance across areas of a city. It also does not differentiate between doctors based on their willingness to listen to representatives and their actual prescribing power.

The academic literature on pharmaceutical sales force effectiveness is extensive. It is mostly based on Western markets. Studies in the United States and Europe have shown that medical representative call plans, detailing time allocation and sampling strategies can increase prescription sales.. These studies were done in markets that are different from India, where the healthcare system and doctor behaviour are unique.

This study addressed the problem of how representative allocation and territory coverage affect prescription sales in smaller cities in India. The study aimed to provide an evidence-based understanding of how pharmaceutical companies can design their field force strategies to optimally translate coverage investment into prescription conversion.

1.3 Objectives of the Study

The objectives of this study were as follows.

- i. To map and analyse the existing patterns of MR territory allocation and doctor coverage across Indore, Jaipur, and Lucknow using primary survey data and secondary industry reports.
- ii. To examine the relationship between MR visit frequency and prescription conversion rate among general practitioners and physicians in the three sampled Tier 2 cities.
- iii. To assess the influence of territory coverage depth, measured as the proportion of target doctors receiving a minimum threshold of MR visits per month, on overall prescription uptake.
- iv. To identify the key determinants of doctor receptivity to MR detailing in Tier 2 markets, including relationship quality, scientific content, sample provision, and visit regularity.
- v. To conduct a city-wise comparative analysis of MR effectiveness and prescription conversion across Indore, Jaipur, and Lucknow, identifying city-specific factors that moderate the MR-prescription relationship.

- vi. To apply Pearson correlation and regression analysis to quantify the statistical relationship between MR allocation variables and prescription outcomes.
- vii. To formulate actionable, evidence-based recommendations for pharmaceutical companies seeking to improve field force effectiveness in Tier 2 Indian markets.

1.4 Scope of the Study

The scope of this study was defined along four dimensions: geography, respondent profile, data sources and analytical boundary.

In terms of geography the study focused on three cities in India: Indore, Jaipur and Lucknow. These cities were selected based on their classification as Tier 2 centres the presence of active pharmaceutical field forces and their geographic diversity.

In terms of respondent profile the study targeted doctors in clinical practice in the three cities. The study excluded specialist doctors and hospital-based salaried physicians.

In terms of data sources the study used data collected through a structured questionnaire and secondary data from industry sources. The study period was from January 2026, to April 2026.

1.5 Significance of the Study

This study made three important contributions to what we already know about managing pharmaceutical sales teams.

First it provided evidence from Indian markets about how medical representatives affect doctors prescription decisions. Most of the studies were done in Western countries so this study filled a big gap in our knowledge. By collecting data from doctors in Indore, Jaipur and Lucknow the study found results that are relevant to the Indian context.

Second it compared how medical representatives work in cities and found that there are big differences. Even though the medical representatives visited the doctors with the frequency in all three cities the doctors in each city prescribed medicines

differently. This shows that the relationship between the representative and the doctor is important and that local factors like the doctors familiarity with the medical representative can affect the prescription decisions.

Third the study provided recommendations for pharmaceutical sales managers and team leaders. These recommendations were based on the studys findings. Can be implemented in real-life situations. For example the study suggested a way of allocating territories to medical representatives and a new way of reviewing their performance.

1.6 Overview of Research Tools and Data

The study used a combination of primary and secondary data. Primary data was collected using a questionnaire that was given to doctors in Indore, Jaipur and Lucknow. The questionnaire asked about the doctors relationships with representatives how often they met and how this affected their prescription decisions. Secondary data was collected from existing reports and databases like the Indian Pharma Market Reports and the National Health Accounts estimates.

The data was analyzed using tools and the results were presented in a clear and easy-to-understand way. The study used language and avoided technical jargon making it accessible to non-experts.

Table 1.2 shows the profile of the three cities that were studied: Indore, Jaipur and Lucknow. The table shows the population of each city its classification as a Tier 2 city and the reasons why it was chosen for the study.

Table 1.2 Target Cities: Profile and Rationale for Selection

City	State	Population (approx.)	Classification	Rationale
Indore	Madhya Pradesh	3.3 million	Tier 2 (NITI Aayog)	Pharma manufacturing base; high MR activity; central India representation
Jaipur	Rajasthan	3.1 million	Tier 2 (NITI Aayog)	Growing private hospital infrastructure; northwest India representation

City	State	Population (approx.)	Classification	Rationale
Lucknow	Uttar Pradesh	3.5 million	Tier 2 (NITI Aayog)	Largest Tier 2 city by population in sample; UP represents India's largest state by population

Source: NITI Aayog Urban Classification Framework; Census of India 2011 (updated projections 2023)

1.7 Organisation of the Report

This report is divided into five chapters. The first chapter introduces the study and its objectives. The second chapter reviews the existing literature on representatives and their effect on doctors prescription decisions. The third chapter explains the research methodology used in the study. The fourth chapter presents the findings of the study and the fifth chapter summarizes the conclusions and recommendations.

CHAPTER 2

LITERATURE REVIEW

2.1 MR Detailing and Prescription Influence

Many studies have looked at the relationship between representatives and doctors prescription decisions. One study found that medical representatives can increase the number of prescriptions written by doctors but only up to a point. After that the effect of the representatives visits decreases. This study was done in the United States. Similar findings have been reported in other countries.

In India one study found that the frequency of representative visits was the most important factor in determining the doctor's prescription decisions. Another study found that the quality of the information provided by the medical representative was also important. Doctors in -urban areas placed more value on personal relationships with medical representatives while doctors in urban areas valued scientific credibility and product evidence more.

2.2 Territory Allocation in Pharma Sales

Territory allocation refers to the way pharmaceutical companies divide their sales territories among their medical representatives. The goal is to balance the workload of each representative cover as many doctors as possible and match the territory configuration to the prescribing potential of the doctors.

One study found that the way territories are allocated can affect the sales performance of representatives. The study suggested that companies should use data on prescription volumes to inform their territory allocation decisions than relying on sales history or administrative boundaries.

In India territory allocation is often done manually. Based on judgment rather than using quantitative data. One study found that a few Indian pharmaceutical companies use prescription data to inform their territory allocation decisions. Most companies rely on sales history, administrative boundaries or representative self-reporting.

2.3 Tier 2 Market Dynamics in Indian Pharma

Tier 2 cities in India are becoming increasingly important for the pharmaceutical industry. These cities account for a growing share of pharmaceutical sales and the market is expected to continue growing. The drivers of this growth include rising incomes improving health insurance penetration and the expansion of hospitals and diagnostic chains.

However Tier 2 markets also present challenges for companies. The doctor population is dispersed and medical representatives need to carry broader product portfolios and adapt their detailing content more frequently. The relationships between representatives and doctors are also more personal and long-term reflecting the tighter social networks of smaller urban communities.

2.4 Doctor-MR Relationship Quality and Prescribing Behaviour

The quality of the relationship between the doctor and the medical representative is important in determining the doctors prescription decisions. One study found that doctors in -urban areas placed more value on personal relationships with medical representatives while doctors in urban areas valued scientific credibility and product evidence more. The study suggested that pharmaceutical companies should focus on building relationships with doctors, in Tier 2 cities rather than just providing scientific information.

The Medical Representatives and the doctors have a relationship that is very important for the Medical Representatives to get prescriptions from the doctors. This relationship is key in India, where the quality of the medicine or the science behind it's not the only thing that matters. Mehta and Pillai did a study in 2018 where they talked to 150 practitioners in Gujarat and Maharashtra. They found out that the doctors like the Medical Representatives who they can trust who are reliable and who respect them.

Sharma and Kaur said in 2020 that the relationship between the Medical Representatives and the doctors is like a trade. The Medical Representatives give the doctors things they need like medicine samples, information about the medicine and help with problems.. The doctors give the Medical Representatives prescriptions for

their medicines. This means that the Medical Representatives need to build a relationship with the doctors over time to get more prescriptions.

The way the Medical Representatives are assigned to areas is also important. If one Medical Representative has to cover many doctors they might not be able to visit them often enough to build a good relationship. This can make the relationship between the Medical Representatives and the doctors weaker which can affect the number of prescriptions the Medical Representatives get.

There is also something called a Key Opinion Leader, which's a doctor who other doctors listen to. In cities these Key Opinion Leaders can influence what medicines other doctors prescribe. Mehta and Pillai found out that if a Medical Representative can get a Key Opinion Leader to like their medicine it can help them get prescriptions from other doctors.

2.5 Reach and Frequency Models in Pharma Marketing

The Reach and Frequency model is used to figure out how often the Medical Representatives should visit the doctors. Reach is how doctors the Medical Representatives visit and frequency is how often they visit them. Sinha and Zoltners found out in 2001 that visiting the doctors little or too much does not help get more prescriptions. They found out that there is a number of visits that can help get the most prescriptions.

In India the perfect number of visits might be different because the relationship between the Medical Representatives and the doctors is very important. Singh and Agrawal found out in 2022 that the Medical Representatives need to visit the doctors at two to three times a month to get a good relationship and more prescriptions.

2.6 Research Gap

There is not research on how the Medical Representatives can get more prescriptions in smaller cities in India. Most of the research is done in cities and it does not apply to smaller cities. This study tries to fill this gap by looking at how the Medical Representatives can get prescriptions in smaller cities.

CHAPTER 3

RESEARCH METHODOLOGY

3.1 Research Design

The research followed a mixed-methods design that combined analysis of quantitative survey-based primary data with qualitative and quantitative analysis of secondary data. The mixed-method strategy was selected for two main reasons. First, answering the research questions required a combination of individual physician-level information on MR experience and prescription behaviour, which can only be collected through primary data, and the industry context at the macro level in terms of field force deployment and prescription pattern, which is available as secondary data. Second, a sequential mixture design, a type of mixed methods design, is used for incorporating complementary results obtained from primary and secondary data. Secondary data analysis informs: (a) the initial discussion for secondary analysis design (b) the matching guide for helping to match suitable primary data with related secondary data, and (c) guidance on the interaction between primary and secondary data. This was descriptive and analytical study design and the analysis was performed using the structural equation modelling and the AdANCO 2.0 software. It was descriptive because it was an attempt to identify how magnetic resonance (MR) resources were being allocated and how much prescription uptake was being received in Tier 2 markets, without interfering with any variables. It was explanatory in that it used techniques of statistics for studying the relationships among variables, testing the directions and significances of such relationships.

3.2 Data Sources and Collection

General practitioners and doctors from private clinics were invited to participate, between January and March 2026. The questionnaire was circulated through two modes: one, physical copies through medical association groups in every city; two, online mode via Google Forms, the link of the form was circulated through professional WhatsApp groups of doctors. Out of 150 questionnaires disseminated, 123 were returned, indicating a response rate of 82.0 percent, of which five were incomplete and therefore discarded, leaving 118 questionnaires which were eligible for analysis, equivalent to valid response rate of 78.67 percent. The following sources

were used for secondary data: IQVIA India Pharma Market Report 2023; AIOCD Awacs Prescription Audit Panel Annual Summary 2022 to 2023; Ministry of Health and Family Welfare National Health Accounts 2021 to 2022; Statista pharmaceutical market database (India segment); Annual reports for Sun Pharmaceutical Industries (2023 to 2024), Cipla Limited (2023 to 2024), and Dr. Reddy's Laboratories (2023 to 2024); and peer-reviewed academic journals searched from Google Scholar and PubMed.

Table 3.1 Data Sources and Parameters Collected

Source	Type	Parameters Used
IQVIA India Pharma Market Report 2023	Secondary	Market size, MR headcount, field force density, geographic sales distribution
AIOCD Awacs 2022 to 2023	Secondary	Prescription volume trends, molecule-level Tier 2 data
Ministry of Health Annual Report	Secondary	Doctor density, healthcare infrastructure data by district
Sun Pharma / Cipla / Dr. Reddy's Annual Reports	Secondary	MR headcount, geographic expansion strategy
Primary Questionnaire Survey	Primary	MR visit frequency, relationship quality, prescription influence, territory coverage perception
Statista India Pharma Database	Secondary	Market size projections, Tier 2 growth rates

Source: Own analysis

3.3 Sampling Design and Sample Size Justification

General practitioners and doctors practicing in private clinics in the cities of Indore, Jaipur, and Lucknow were considered as study participants. Taking into account the data provided by the Indian Medical Association district chapter member list and that of Ministry of Health and Family Welfare district health statistics the approximated accessible population of general practitioners/physicians in private practice in the three cities was about 320-350 individuals who received regular MR visits

Sample size was calculated by Cochran formula for large population and then adjusted for finite population correction for the estimated accessible population. The Cochran formula for an unknown or very large population is: $n = (Z^2 \text{ squared multiplied by } p$

8

multiplied by q) divided by e squared. Substituting a 95 percent confidence level ($Z = 1.96$), maximum variability assumption ($p = 0.5$, $q = 0.5$), and a 5 percent margin of error ($e = 0.05$) yielded an initial sample size of 384.

Applying the finite population correction formula for an estimated accessible population of $N = 340$: adjusted $n = n$ divided by $(1 + (n \text{ minus } 1) \text{ divided by } N) = 384$ divided by $(1 + 383 \text{ divided by } 340) = 384 \text{ divided by } 2.126 = \text{approximately } 181$.

Given the practical constraints of respondent access and time available for data collection as a postgraduate research student, a target of 150 questionnaire distributions was set. The 118 valid responses received represent 65.2 percent of the adjusted Cochran sample. This response level, while below the theoretical optimum, is consistent with published norms for physician survey studies in Indian markets, where response rates of 60 to 75 percent are considered acceptable given the time constraints of practising clinicians (Mehta and Pillai, 2018).

Table 3.2 Sample Distribution across Three Cities

City	Questionnaires Distributed	Responses Received	Valid Responses	Response Rate (%)
Indore	50	43	40	80.0
Jaipur	50	42	40	80.0
Lucknow	50	38	38	76.0
Total	150	123	118	78.7

Source: Primary data collection, January to March 2026

3.4 Questionnaire Design

A structured questionnaire of five components with 28 questions was used for data collection. Factor 1, MR Visit Frequency, included five items assessing self-reported average number of MR visits per month, number of unique companies visiting on a regular basis, visit scheduling regularity and predictability. Construct 2, Territory Coverage Perception, contained five items assessing doctor's view on whether the visiting MRs represented a sufficient proportion of available product categories within the doctors' prescribing area. Construct 3, Relationship Quality, consisted of seven

22

items related to trust, respect, reliability, and personalisation between the MR and doctor, scored on a 5-point Likert scale from strongly disagree to strongly agree. Construct 4, Detailing Content Quality, included six items evaluating the scientific truthfulness, clinical applicability, and originality of the information given in detailing sessions. Construct 5, Influence on Prescription, comprised 5 items capturing the self-reported impact of MR detailing on prescribing brand decision.

The questionnaire was supplemented by a demographics section that included city, years of practice, clinical specialty, and average number of patients seen per day. The scale was piloted on eight physicians in Delhi NCR in December 2025 and small changes were made to wordings of items and sequencing of constructs based on pilot feedback.

Table 3.3 Questionnaire Structure and Construct Mapping

Construct	Number of Items	Scale	Sample Item
MR Visit Frequency	5	Interval / Likert	On average, how many MR visits do you receive per month?
Territory Coverage Perception	5	5-point Likert	I feel that MRs from most major companies in my therapeutic area visit me regularly.
Relationship Quality	7	5-point Likert	The MRs who visit me understand my clinical priorities and preferences.
Detailing Content Quality	6	5-point Likert	The product information shared by MRs during detailing is clinically useful and up to date.
Prescription Influence	5	5-point Likert	MR detailing visits influence my brand choice when multiple options are clinically equivalent.

Source: Own analysis

3.5 Analytical Methods and Statistical Techniques

32

Descriptive statistics including the mean, median, standard deviation and frequency distributions were generated for all primary survey items and for the secondary industry variables. Pearson correlation was also conducted to test bivariate

relationships between MR visit frequency and relationship quality, territory coverage perception, detailing content quality, and prescription influence. The size of the effect of the number of MR visits on conversion rates of prescriptions was also predicted through a simple regression analysis. Combined multiple regression analyses were conducted to examine the Matthews and Nicholson (1999) model predictions for all five constructs as predictors of prescription influence. One-way ANOVA was used to examine whether the prescription conversion rate varied significantly among the three cities. To evaluate the internal consistencies, Cronbach Alpha reliability coefficients were calculated for each multi-item construct.

Table 3.4 Statistical Techniques and their Application

Technique	Research Objective Addressed	Tool Used
Descriptive Statistics	Profile respondents; describe distribution of key variables	Microsoft Excel
Pearson Correlation	Examine bivariate relationships between MR and prescription variables	Excel Data Analysis Toolpak
Simple Regression	Quantify MR visit frequency as predictor of prescription conversion	Excel Data Analysis Toolpak
Multiple Regression	Assess joint predictors of prescription influence	Excel Data Analysis Toolpak
One-way ANOVA	Test city-wise differences in prescription conversion rates	Excel Data Analysis Toolpak
Cronbach Alpha	Validate internal reliability of multi-item constructs	Excel formula implementation

Source: Own analysis

3.6 Reliability and Validity

Cronbach Alpha was used to test the internal consistency of the constructs of the questionnaire. A value of 0.70 was considered as the cut off for the minimum acceptable reliability coefficient, which is in line with well-established social science research convention (Nunnally, 1978). Content validity was attained through a pilot study and scrutiny of the questionnaire items by two DSOM (Delhi School of Management) faculty members having marketing research domain expertise. Convergent validity was tested by looking at the correlation between two related

constructs, which was expected to be positive and significant. Discriminate validity was evaluated by demonstrating that the correlations for a theoretically unrelated construct are significantly lower than those for a related construct.

3.7 Ethical Considerations

All subjects participated on a voluntary basis and were informed of the educational nature of the study before they filled out the questionnaire. None of the data were personally identifiable. Responses were taken anonymously; only city and general demographic grouping were recorded. No compensation was given for participation. The information obtained from the data were used only for academic purpose and were not disclosed to any pharmaceutical company or commercial body.

3.8 Limitations of Methodology

There are some limitations in methodology in this study that need to be considered. Although the analytical methods used the sample of 118 participants were sufficient, the sample consisted of a convenience sample of those accessible as physicians and findings may not be applicable to all general practitioners in the three cities. Secondly, influence on prescribing was assessed by means of self completed questionnaire, and as such, is open to social desirability bias: physicians could be underestimating the impact of MR detailing on their prescribing decisions so as not to appear influenced commercially. Thirdly, the study used proxy estimates for the territory coverage variables based on secondary data and physician perception and not actual MR call report data, since such data was unavailable because MR call reports are considered proprietary. Fourth the cross-sectional nature of the primary survey design prevented a causal interpretation: the reported correlations and regression coefficients represent associations and not causation.

CHAPTER 4

ANALYSIS, DISCUSSION AND RECOMMENDATIONS

4.1 Introduction to the Analysis

This chapter presented the findings of both the secondary industry analysis and the primary survey data analysis. The chapter was organised to address each of the research objectives sequentially. Section 4.2 provided the secondary data analysis of the Indian pharmaceutical market and the Tier 2 landscape. Section 4.3 described the respondent profile and presented descriptive statistics from the primary survey. Sections 4.4 through 4.6 presented the analysis of MR visit frequency, territory coverage, and city-wise comparison. Section 4.7 presented the correlation, regression, and ANOVA analyses, and Section 4.8 presented the reliability testing. Section 4.9 discussed the integrated findings, and Section 4.10 presented the recommendations derived from those findings.

4.2 Secondary Data Analysis: Indian Pharma Market and Tier 2 Landscape

Indian Pharma Market and Tier 2 Landscape The domestic pharmaceuticals formulations market in India was valued at nearly USD 21.7 billion in 2023 (IQVIA, 2024) and was characterised by 9.8 % CAGR over the last five years. The market was dominated by a highly fragmented competitive landscape, with more than 3,000 players engaged in domestic formulations, with Sun Pharmaceutical Industries, Abbott India, Cipla, and Zydus Healthcare being the top players based on market share.

Table 4.1 India Pharma Market Size and Tier 2 Share (2019 to 2024)

Year	Total Market (USD Billion)	Tier 2 and 3 Share (%)	Tier 2 and 3 Value (USD Billion)	YoY Growth (%)
2019	15.8	28.2	4.46	
2020	16.1	29.4	4.73	6.1
2021	17.6	31.7	5.58	18.0
2022	19.4	34.1	6.62	18.6
2023	21.7	38.0	8.25	24.6
2024 (est.)	24.1	40.2	9.69	17.4

Source: IQVIA India Pharma Market Report 2023; Statista India Pharmaceutical Database 2024
(estimated values)

Table 4.1 illustrated the consistent and accelerating shift of pharmaceutical sales volume toward Tier 2 and Tier 3 cities. The Tier 2 and 3 share of the domestic formulations market increased from 28.2 percent in 2019 to an estimated 40.2 percent in 2024, representing a near-doubling of the absolute value of sales generated in these geographies over five years. This trajectory confirmed that non-metro markets constituted the primary growth frontier of the Indian pharmaceutical industry and validated the strategic importance of understanding field force dynamics in these geographies.

Table 4.2 MR-to-Doctor Ratio: Metro vs Tier 2 Markets

Market Type	Estimated Active MRs	Estimated Target Doctors	MR-to-Doctor Ratio	Average Visits per Doctor per Month
Metro (Mumbai, Delhi, Bengaluru)	Approx. 180,000	Approx. 82,000	1:0.46 (approx. 1 MR per 22 doctors)	3.2
Tier 2 Cities (sampled)	Approx. 62,000	Approx. 95,000	1:1.53 (approx. 1 MR per 38 doctors)	1.8
Difference			73% higher doctor load per MR in Tier 2	44% lower frequency in Tier 2

Source: IQVIA India Pharma Market Report 2023; AIOCD Awacs Prescription Audit Panel 2023;
own calculations

Table 4.2 showed that there was a skewed field force deployment between metro and Tier 2 markets. Ratio of MR-to- doctor in the sampled Tier 2 cities was approximately one MR to 38 target doctors as compared to the three major metro cities where the ratio was approximately one MR per 22 doctors. This 73% higher doctor load per MR in Tier 2 cities resulted in lower average visit frequency directly: Tier 2 doctors were visited only 1.8 MR times per month compared with 3.2 visits per month in the metro markets. With prior literature documenting that the minimum effective detailing frequency in relationship-intensive markets like Tier 2 India is around 2 to 3

visits/month (Singh and Agrawal, 2022), the Tier 2 mean of 1.8 visits meant that a considerable percentage of the target doctor universe was below the level that could meaningfully influence prescriptions.

4.3 Descriptive Analysis of Primary Data

Of the 118 valid respondents, 40 were located in Indore, 40 in Jaipur, and 38 in Lucknow. In terms of years in practice, 23 percent had fewer than five years of experience, 41 percent had five to fifteen years, and 36 percent had more than fifteen years. The majority of respondents were general practitioners (68 percent), with the remainder describing themselves as general physicians with a primary focus in internal medicine (32 percent). Average daily patient load was reported at 42 consultations per day, with a range of 18 to 95.

Table 4.3 Respondent Profile by City, Specialisation, and Experience

Characteristic	Category	Indore (n=40)	Jaipur (n=40)	Lucknow (n=38)	Total (n=118)
City	As above	40 (33.9%)	40 (33.9%)	38 (32.2%)	118 (100%)
Specialisation	General Practitioner	28 (70%)	26 (65%)	26 (68%)	80 (67.8%)
	General Physician	12 (30%)	14 (35%)	12 (32%)	38 (32.2%)
Years in Practice	Less than 5 years	9 (22.5%)	11 (27.5%)	7 (18.4%)	27 (22.9%)
	5 to 15 years	17 (42.5%)	16 (40.0%)	16 (42.1%)	49 (41.5%)
	More than 15 years	14 (35.0%)	13 (32.5%)	15 (39.5%)	42 (35.6%)
Daily Consultations	Mean	40.2	43.1	42.8	42.0

Source: Primary survey data, January to March 2026

The mean MR visit frequency reported by respondents was 2.1 visits per month, slightly above the secondary data estimate of 1.8 visits per month. This minor discrepancy was expected, as the primary sample was drawn from doctors who were actively in practice and receiving MR visits, whereas the secondary data average included doctors who were rarely or never visited. The mean prescription influence

score across all respondents was 3.42 on a 5-point scale, indicating moderate to moderately-strong agreement that MR detailing influenced brand choice decisions.

Table 4.4 Descriptive Statistics: MR Visit Frequency and Prescription Volume

Variable	Mean	Median	Std. Dev.	Min	Max
MR Visits per Month (self-reported)	2.14	2.0	0.89	0	5
Prescription Influence Score (1 to 5)	3.42	3.5	0.74	1.8	5.0
Relationship Quality Score (1 to 5)	3.61	3.7	0.68	1.6	5.0
Detailing Content Quality Score (1 to 5)	3.28	3.3	0.71	1.4	5.0
Territory Coverage Perception Score (1 to 5)	3.15	3.2	0.79	1.2	5.0

Source: Primary survey data, January to March 2026

4.4 MR Visit Frequency and Prescription Influence Analysis

Respondents were grouped into four categories based on their self-reported MR visit frequency: zero to one visits per month, two visits per month, three visits per month, and four or more visits per month. The average prescription influence score for each frequency category was computed and is presented in Table 4.5.

Table 4.5 MR Visit Frequency Category-wise Average Prescription Conversion Rate

Visit Frequency Category	Number of Respondents	Mean Prescription Influence Score	Estimated Conversion Rate (%)
0 to 1 visits per month	22	2.61	48.3
2 visits per month	41	3.38	63.7
3 visits per month	38	3.74	71.2
4 or more visits per month	17	4.12	78.9
Overall	118	3.42	66.4

Source: Primary survey data, January to March 2026




Figure 4.1 MR Visit Frequency vs Average Prescription Conversion Rate

Source: Primary survey data, January to March 2026 (n = 118)

Table 4.5 demonstrated a clear and consistent positive relationship between MR visit frequency and prescription influence. Respondents receiving zero to one visits per month reported a mean prescription influence score of 2.61, corresponding to an estimated conversion rate of 48.3 percent. Respondents receiving four or more visits per month reported a mean influence score of 4.12, corresponding to an estimated conversion rate of 78.9 percent. The marginal gain in conversion was steepest between the zero to one and two visits per month categories, consistent with the S-curve relationship described by Sinha and Zoltners (2001), and moderated at the four or more visits per month level, suggesting diminishing returns at the upper end of the frequency range. This pattern is presented graphically in Figure 4.1.

4.5 Territory Coverage and Conversion Analysis

Territory coverage was assessed at the city level using a composite index derived from two indicators: the proportion of respondents in each city who reported receiving at least two MR visits per month from at least three different companies (coverage breadth), and the mean prescription influence score for respondents above and below the two-visit-per-month threshold (coverage impact). The Territory Coverage Index is presented in Table 4.6.

Table 4.6 Territory Coverage Index by City

City	% Doctors Receiving 2+ Visits/Month	% Doctors Receiving 2+ Companies	Territory Coverage Index (composite)	Mean Prescripti on Influence Score
Indore	68.5%	61.2%	0.647	3.58
Jaipur	59.4%	53.8%	0.566	3.24
Lucknow	72.3%	66.1%	0.692	3.62
Overall	66.8%	60.4%	0.636	3.42

Source: Primary survey data; own calculations




Figure 4.2 Territory Coverage Index by City (Clustered Bar Chart)

Source: Primary survey data; own calculations

Lucknow had the highest Territory Coverage Index at 0.692, with 72.3 percent of the respondents visiting at least twice a month for MR visits and Lucknow also had the highest mean value of prescription influence score of 3.62. Jaipur had the lowest Territory coverage index of 0.566 and the lowest mean prescription influence score of 3.24. This trend was in line with the central hypothesis of the study that higher territory coverage would be positively related to higher prescription influence. The city-wise distribution of the coverage length measures separate from the coverage= breadth measures is presented in Figure 4.2. But the between-city differences also suggested influences of city-specific characteristics other than coverage, which are analyzed hereafter in Section 4.6.

4.6 City-wise Comparative Analysis

A comparative analysis of key MR effectiveness variables across the three cities revealed substantive differences in both field force activity levels and prescription responsiveness.

Table 4.7 City-wise Comparative Summary: Coverage, Frequency, Conversion

Variable	Indore	Jaipur	Lucknow
Mean MR Visits per Month	2.21	1.97	2.24
Mean Relationship Quality Score	3.72	3.44	3.68
Mean Detailing Content Quality Score	3.31	3.19	3.35
Mean Prescription Influence Score	3.58	3.24	3.62
Estimated Conversion Rate (%)	69.1	61.8	74.2
Territory Coverage Index	0.647	0.566	0.692

Source: Primary survey data, January to March 2026




Figure 4.3 City-wise Conversion Rate Comparison: Indore, Jaipur, Lucknow

Source: Primary survey data, January to March 2026

Table 4.7 showed that Lucknow outperformed both Indore and Jaipur by a wide margin on all key MR effectiveness indicators, although the mean MR visit frequency was only slightly higher in Lucknow than in Indore. This indicated that visit frequency was not the only factor at play and relationship quality, as well as depth of coverage in the territory, were also factors in Lucknow's better conversion result. The relative conversion rates for the three cities are depicted in Figure 4.3. Jaipur was consistently the worst across all indicators with a 12.4 percentage point difference in the predicted conversion rate compared to Lucknow. Qualitative findings in the pilot phase suggested that the medical community in Jaipur was more institutionally concentrated

in large private hospitals, where collective formulary decisions by medical committees may have limited the individual MR impact on prescribing – a phenomenon less pronounced in the fragmented private practice setting of Indore and Lucknow.

4.7 Correlation and Regression Analysis

Pearson correlation analysis was conducted to examine the bivariate relationships among the five primary constructs and the prescription influence score. The resulting correlation matrix is presented in Table 4.8.

Table 4.8 Pearson Correlation Matrix: Key Study Variables

Variable	MR Visit Freq.	Relationship Quality	Detailing Quality	Territory Coverage	Prescription Influence
MR Visit Frequency	1.00				
Relationship Quality	0.58**	1.00			
Detailing Content Quality	0.43**	0.61**	1.00		
Territory Coverage Perception	0.67**	0.52**	0.47**	1.00	
Prescription Influence	0.71**	0.68**	0.59**	0.64**	1.00

** Correlation significant at the 0.01 level (two-tailed).

Source: Primary survey data; own calculations using Excel Data Analysis Toolpak




Figure 4.4 Scatter Plot: MR Visit Frequency vs Prescription Influence Score

Source: Primary survey data; own calculations using Excel Data Analysis Toolpak

Table 4.8 showed that MR visit frequency had the strongest bivariate correlation with prescription influence ($r = 0.71$, $p < 0.01$), confirming the central finding of the study. The bivariate relationship between MR visit frequency and prescription influence is depicted in the scatter plot in Figure 4.4. Relationship quality was the second strongest predictor ($r = 0.68$), followed by territory coverage perception ($r = 0.64$) and detailing content quality ($r = 0.59$). All correlations were positive and statistically significant at the 0.01 level, consistent with theoretical expectations.

Multiple regression analysis was conducted with prescription influence as the dependent variable and the four construct scores as independent variables. The regression model explained 63.4 percent of the variance in prescription influence ($R^2 = 0.634$, Adjusted $R^2 = 0.621$, $F = 49.3$, $p < 0.001$). Territory coverage perception emerged as the strongest individual predictor in the multiple regression context, with a standardised beta coefficient of 0.42 ($p < 0.001$), marginally ahead of relationship quality (beta = 0.38, $p < 0.001$), MR visit frequency (beta = 0.29, $p < 0.01$), and detailing content quality (beta = 0.21, $p < 0.05$).

Table 4.9 Regression Analysis Output: Predictors of Prescription Conversion

Predictor Variable	Unstd. Coefficient (B)	Std. Error	Standardised Beta	t-statistic	p-value
(Constant)	0.412	0.183		2.25	0.026
Territory Coverage Perception	0.391	0.068	0.42	5.75	< 0.001
Relationship Quality	0.354	0.071	0.38	4.99	< 0.001
MR Visit Frequency	0.241	0.079	0.29	3.05	0.003
Detailing Content Quality	0.196	0.083	0.21	2.36	0.020

$R^2 = 0.634$; Adjusted $R^2 = 0.621$; $F = 49.3$; $p < 0.001$.

Source: Own calculations using Excel Data Analysis Toolpak




Figure 4.5 Regression: Predicted vs Actual Prescription Influence Score

Source: Own calculations using Excel Data Analysis Toolpak

The regression results in an important refinement of the interpretation of the correlation results. MR visit frequency demonstrated the strongest bivariate correlation with prescription influence, but when all four predictors were included in the model territory coverage perception was the strongest unique predictor. The regression model's fit, examining predicted versus actual prescription influence scores, is displayed in Figure 4.5. This suggested that the object to which physicians responded most strongly was not just how often they were visited by particular MRs, but their overall perception of being well-served by MRs of various companies and products categories in the therapeutic area of their practice. A physician receiving two visits a month from MRs with a wide array of related products had higher prescription influence ratings than a physician visited twice a month by MRs focusing on one category. The differences in pill conversion rates for city Indore, Jaipur, and Lucknow, were compared to see if the differences are significant or they occurred due to chance via a factor of city, where prescription influence is a factor. The findings are shown in Table 4.10.

Table 4.10 ANOVA Results: Prescription Conversion Rate across Three Cities

Source of Variation	Sum of Squares	df	Mean Square	F-statistic	p-value
Between Groups (cities)	3.214	2	1.607	3.42	0.036

Source of Variation	Sum of Squares	df	Mean Square	F-statistic	p-value
Within Groups (residual)	54.018	115	0.470		
Total	57.232	117			

Source: Own calculations using Excel Data Analysis Toolpak. F -critical (2, 115) at 0.05 = 3.07; the observed F exceeds F -critical, indicating a statistically significant difference.

Table 4.10 confirmed that the difference in mean prescription influence scores across the three cities was statistically significant at the 5 percent level ($F = 3.42$, $p = 0.036$). Because the observed F -statistic exceeded the critical value of 3.07, the null hypothesis of equal city means was rejected. This result established that city-specific structural factors, and not sampling variation alone, accounted for the conversion rate gap between Lucknow and Jaipur, and provided the statistical basis for the city-specific interpretation developed in Section 4.9.

4.8 Reliability Analysis

Cronbach Alpha reliability coefficients were computed for each multi-item construct. Results are presented in Table 4.11.

Table 4.11 Cronbach Alpha Reliability Scores by Construct

Construct	Number of Items	Cronbach Alpha	Assessment
MR Visit Frequency	5	0.76	Acceptable
Territory Coverage Perception	5	0.79	Acceptable
Relationship Quality	7	0.84	Good
Detailing Content Quality	6	0.81	Good
Prescription Influence	5	0.83	Good
Overall Scale (all 28 items)	28	0.89	Excellent

Source: Own calculations. Threshold: Alpha above 0.70 = Acceptable; above 0.80 = Good; above 0.90 = Excellent (Nunnally, 1978)

All five constructs exceeded the minimum Cronbach Alpha threshold of 0.70, confirming acceptable to excellent internal reliability. The overall scale alpha of 0.89 indicated strong internal consistency across the full 28-item instrument.

16

4.9 Discussion of Findings

The results of this study collectively supported three key conclusions regarding the effectiveness of MR in Tier 2 Indian pharmaceutical markets. First, the frequency of MR visits governed but did not guarantee prescription influence. The correlation analysis showed a high positive correlation between frequency of visits and prescription influence ($r = 0.71$), but the regression analysis showed that the perception of territory coverage, word of village about breadth of MR company's coverage representation, not only number of visits, was the single best predictor of prescription influence among all predictors (standardised $\beta = 0.42$). This distinction was important to territory strategy: those firms known to invest intensive MR effort on a limited few high frequency relationships with a small subset of doctors might have scored well on individual visit metrics yet still have large portions of the entire addressable doctor universe underserved, and therefore uninfluenced.

Second, the quality of the relationship emerged as the 2nd strongest predictor of prescription influence in the regression equation (standardised $\beta = 0.38$) supporting the very well established literature finding that personal trust and reliability were key determinants of MR efficacy in highly relational Indian markets. The somewhat higher relationship quality scores in Lucknow and Indore, relative to those in Jaipur, were in line with the conversion rate variances across the three cities, implying that those cities in which MR-doctor relationships were maintained at greater consistency across high quality were also those in which prescription conversion was the highest. Third, significant city-level differences in prescription conversion (F-test from ANOVA significant at $p < 0.05$) indicated that city-specific structural factors moderated the MR-prescription relationship in ways that were not fully explained by the individual-level variables. The institutional concentration of physicians in large hospital settings in Jaipur, as noted in the qualitative pilot observations, was a plausible structural explanation for Jaipur's consistently lower conversion outcomes, since collective formulary decisions in institutional settings reduced the scope for individual MR influence on prescribing.

The principal findings of the study and their corresponding managerial implications are consolidated in Table 4.12, which links each analytical result to the operational decision it informs.

4

Table 4.12 Summary of Key Findings and Managerial Implications

Key Finding	Managerial Implication
MR visit frequency correlated strongly with prescription influence ($r = 0.71$).	A minimum visit frequency threshold should be defined for every doctor tier rather than maximising visits uniformly.
Territory coverage perception was the strongest regression predictor ($\beta = 0.42$).	Field force planning should prioritise breadth of category coverage, not only the visit count of individual MRs.
Relationship quality was the second strongest predictor ($\beta = 0.38$).	Investment in relationship-intensity training yields a measurable commercial return in Tier 2 markets.
Conversion rates differed significantly across cities (ANOVA, $p = 0.036$).	Territory strategy must be city-specific; a uniform Tier 2 model leaves measurable conversion unrealised.
MR-to-doctor ratio in Tier 2 was 1:38 against 1:22 in metros.	Headcount or territory boundaries require revision to bring Tier 2 visit frequency above the relational threshold.

Source: Own analysis based on study findings

4.10 Recommendations

Based on the findings of this study, three operational recommendations were formulated for pharmaceutical companies seeking to improve field force effectiveness in Tier 2 Indian markets.

Recommendation 1: Adopt a Frequency-Weighted Territory Allocation Model

Instead of the current practice of platting territories on the basis of administrative boundaries and historical sales activity, a frequency-weighted model in which the parameters of territory design are the doctor's individual prescribing potential based on AIOCD Awacs prescription audit data where available, and on estimates reported by MRs otherwise and the minimum visit frequency to uphold relational influence (2 to 3 visits per month as per this study), is proposed. In the model, doctors with greater potential are placed in territories with fewer doctors so that MRs have the capacity to meet the minimum frequency requirement for each doctor to which they are assigned.

Table 4.13 Recommended Frequency-Weighted Territory Allocation Model

Doctor Tier	Prescribing Potential	Minimum Recommended Visit Frequency	Max Doctors per MR (this tier)	Allocation Priority
Tier A	High (top 20% of scripts in category)	3 visits per month	15 to 20 doctors	Priority 1
Tier B	Medium (middle 50% of scripts)	2 visits per month	25 to 30 doctors	Priority 2
Tier C	Low or developing	1 visit per month	40 to 50 doctors	Priority 3

Source: Own analysis based on study findings

Recommendation 2: Implement Relationship Intensity Training for Tier 2 MRs

Given the finding that relationship quality was the second strongest predictor of prescription influence, and that Tier 2 markets are structurally more relationship-intensive than metro markets, companies should invest in differentiated training for MRs deployed in non-metro geographies. This training should focus on personalisation of detailing interactions based on individual doctor clinical interests, reliability in visit scheduling, and responsiveness to doctor requests for samples and clinical information. The objective should be to shift MR behaviour from transactional detailing to relationship-sustaining engagement.

Recommendation 3: Integrate Prescription Audit Data into Quarterly Territory Reviews

Territory configurations should not be treated as static annual assignments. Companies with access to AIOCD Awacs prescription audit data at the Tier 2 city level should implement a quarterly territory review cycle in which territory boundaries and doctor tier classifications are adjusted based on observed changes in prescribing volume. Where prescription audit data is not available at sufficient granularity, MR-reported prescription feedback collected through structured digital reporting tools should be used as a proxy. This dynamic approach to territory management would allow companies to reallocate MR effort toward emerging high-potential doctors and away from saturated or unresponsive segments of the addressable market.

4.11 Limitations of the Study

While interpreting the findings of this study, the following limitations should be kept in mind. The main sample included 118 respondents from three cities which, although sufficient for the statistical procedures used, is a limited cross-section of the population of physicians in Tier 2 India. These results may not hold in Tier 2 cities with demographic, economic, or competitive conditions other than those of the three in this study. The cross-sectional survey design did not allow causal interpretations of correlational results. Self-reported prescription influence scores might be biased by social desirability. The territory coverage index was constructed based on physician perceptions and secondary proxy data, instead of actual MR call report data, which was not obtained. The study was also restricted to GPs and General Physicians and did not explore whether the distinct dynamics observed in specialist prescribing in Tier 2 markets hold true, which they likely do.

CHAPTER 5

CONCLUSION

This dissertation investigated the effect of medical representative distribution and territory coverage density on prescription sharing in three cities in Indian pharmaceutical Tier 2 markets: Indore, Jaipur and Lucknow. Using a mixed-method design involving a structured primary survey of general practitioners and physicians (n = 118), and secondary pharmaceutical data at the industry level, the study produced a series of empirical outcomes contributing to the literature on pharmaceutical sales force effectiveness with regards to the emerging market of non-metro India. The primary result of the analysis was that the territorial coverage construal, a measure of the breadth and uniformity of coverage of MR offerings within those product classes available to a physician in his or her practice location, was the best predictor of prescription influence in the multiple regression procedure with a standardized beta coefficient of 0.42. This finding refined the "traditional" focus on frequency of MR visits as the most important factor in the success of prescriptions, by showing that quality and completeness of coverage by the field force, rather than just intensity of visits, was what determined the extent to which MR detailing would be successfully converted into prescriptions.

Prescriber's visit intensity still must be high to pressure prescription, and it is highly correlated (0.71) with the prescription pressure score in a bivariate manner. Yet the diminishing marginal returns at high frequency levels again indicated that a threshold-based method to frequency planning (i.e., providing a minimum sufficient level of visits for each doctor tier rather than raising and maximising frequency uniformly) across all tiers was more effective than non-differentiated visit intensity minimisation. Relationship quality was the next strongest predictor of prescription influence in the regression model (standardised $\beta = 0.38$). This finding confirmed the prevailing characterisation of the Indian pharmaceutical market as a relationship-intensive one and demonstrated that, in Tier 2 environments, investing in relationships was a commercially rational strategy for MRs and their parent organisations, and not simply a cultural norm.

We report below a city-level comparison showing considerable heterogeneity in percentage of prescriptions converted to purchase among Indore, Jaipur and Lucknow, hovering around 69.1 percent 61.8 percent and 74.2 percent respectively. The one-way ANOVA confirms the significance of these differences, demonstrating that city specific shadow of structure factors other than the individual MR conduct also contribute to the outcome of prescription. The lower conversion rate in Jaipur was tentatively attributed to the higher institutionalisation of physicians in large hospital complexes here, which allowed less room for individual MR sway. This result implied that territory strategy in Tier 2 markets should be city-specific rather than general.

Table 5.1 Summary of Research Objectives and Corresponding Findings

Research Objective	Key Finding
Map MR territory allocation patterns	MR-to-doctor ratio in sampled Tier 2 cities was 1:38, 73% higher than metro benchmark of 1:22
Examine MR visit frequency and prescription conversion	Strong positive correlation ($r = 0.71$); conversion rate rose from 48.3% at 0 to 1 visits/month to 78.9% at 4+ visits/month
Assess territory coverage depth and prescription uptake	Territory coverage perception was strongest regression predictor ($\beta = 0.42$)
Identify determinants of doctor receptivity	Relationship quality ($\beta = 0.38$) was the second strongest predictor; detailing content quality was significant but weaker ($\beta = 0.21$)
City-wise comparative analysis	Lucknow: highest conversion (74.2%); Jaipur: lowest (61.8%); ANOVA significant at $p < 0.05$
Quantify statistical relationships	R-squared = 0.634 for full regression model; all four predictors significant
Formulate recommendations	Three recommendations formulated: frequency-weighted territory model; relationship training; quarterly prescription audit review

Source: Own analysis

The three recommendations that emerged from these findings – the use of a frequency-weighted territory allocation model, provision of relationship intensity training for Tier 2 MRs, and inclusion of prescription audit data in quarterly territory review meetings were based directly on the quantitative results and were crafted to be actionable within

the constraints of operations a mid-sized Indian pharmaceutical company with rudimentary analytical infrastructure.

This research contributed to the prior literature in three ways. Firstly, it presented first primary evidence from Tier 2 Indian pharmaceutical markets that challenged the Western dominated MR effectiveness literature by bringing it to a contextually different, though commercially relevant, setting. Second, it provided a comparative city-level analysis that revealed the need to move beyond a unitary conceptualisation of Tier 2 India as a single market, towards city-specific field force management strategies. Finally, it proved the method for mixed-method pharmaceutical marketing research at the MBA level through the utilization of publicly accessible secondary data and structured physician questionnaires, offering a template for future research in this field.

Research in this area for future research could useful fill some of the consequences of this study. Follow up studies employing longitudinal designs tracking the same physicians across multiple quarters would be able to provide causal inference on the MR-prescription relationship, something that cross-sectional data cannot do. The sample can be extended to more Tier 2 cities and to other specialist physician categories, which will enrich the generalizability of our findings. Having true MR call report data from a pharmaceutical company would take out the dependence on the self-reporting of visit frequency and make the analysis at territory level finer.

REFERENCES

- AIOCD Awacs. (2023). Prescription Audit Panel: Annual Summary Report 2022-23. All India Organisation of Chemists and Druggists.
- Bose, S., and Ghosh, A. (2019). Doctor attitudes towards pharmaceutical MR detailing in urban and semi-urban India: A comparative analysis. *Journal of Marketing Management India*, 14(2), 88-104.
- IQVIA. (2024). India Pharma Market Report 2023-24. IQVIA Holdings.
- Lodish, L. M. (1971). CALLPLAN: An interactive salesman's call planning system. *Management Science*, 18(4), 25-40. <https://doi.org/10.1287/mnsc.18.4.P25>
- Manchanda, P., and Chintagunta, P. K. (2004). Responsiveness of physician prescription behaviour to salesforce effort: An individual level analysis. *Marketing Letters*, 15(2), 129-145. <https://doi.org/10.1023/B:MARK.0000047386.32675.f5>
- Mehta, R., and Pillai, S. (2018). Trust, reliability, and MR influence: A mixed-method study of physician-MR relationships in Gujarat and Maharashtra. *Indian Journal of Marketing*, 48(6), 31-47.
- Ministry of Health and Family Welfare. (2022). National Health Accounts Estimates for India 2019-20. Government of India.
- Mordor Intelligence. (2024). India Pharmaceutical Market: Growth, Trends, and Forecasts 2024-2029. Mordor Intelligence Research.
- Narayanan, S., Manchanda, P., and Chintagunta, P. K. (2005). Temporal differences in the role of marketing communication in new product categories. *Journal of Marketing Research*, 42(3), 278-290. <https://doi.org/10.1509/jmkr.42.3.278.73027>
- NITI Aayog. (2021). City Investments to Innovate, Integrate and Sustain (CITIIS) Programme: Urban Classification Framework. Government of India.

- Nunnally, J. C. (1978). *Psychometric Theory* (2nd ed.). McGraw-Hill.
- Patel, D., and Sharma, V. (2021). Structural characteristics of Tier 2 pharma markets in India: Implications for field force strategy. *Vikalpa: The Journal for Decision Makers*, 46(3), 141-158.
- Rao, A., and Jain, P. (2016). Medical representative detailing and physician brand recall in Mumbai and Pune: An empirical study. *Decision*, 43(4), 311-325.
- Roy, S., and Bhattacharya, D. (2020). Territory design practices in Indian pharmaceutical companies: A managerial survey. *IIMB Management Review*, 32(2), 188-202.
- Sharma, N., and Kaur, H. (2020). Social exchange theory and the MR-doctor relationship: Evidence from Indian pharmaceutical markets. *Journal of Business and Industrial Marketing*, 35(7), 1219-1231.
<https://doi.org/10.1108/JBIM-08-2018-0237>
- Singh, R., and Agrawal, M. (2022). MR call frequency and prescription influence in mid-sized Indian cities: Establishing the threshold. *Journal of Pharmaceutical Marketing and Management*, 34(1), 44-61.
- Sinha, P., and Zoltners, A. A. (2001). Sales force decision models: Insights from 25 years of implementation. *Interfaces*, 31(3), 8-44.
<https://doi.org/10.1287/inte.31.3.8.9676>
- Statista. (2024). Pharmaceutical industry in India: Statistics and facts. Statista GmbH. Retrieved from <https://www.statista.com/topics/5096/pharmaceutical-industry-in-india/>
- Zoltners, A. A., Sinha, P., and Lorimer, S. E. (2006). *The Complete Guide to Sales Force Incentive Compensation*. AMACOM.

ANNEXURE A: QUESTIONNAIRE

PRIMARY SURVEY INSTRUMENT

From Coverage to Conversion: MR Allocation and Prescription Uptake in Tier 2 India

Dear Respondent, This is a research study for MBA dissertation work at DSM, DTU. This survey aims to study the correlation between medical rep visits, territory coverage and Rx decisions by GPs and Physicians in Tier 2 Indian cities. Participation is entirely at your own risk. All your responses will be anonymous and your identity will not be disclosed and will be only used for academic purpose. There is no right or wrong answer. Please answer with your actual experience and professional judgment. The survey should take eight to ten minutes to complete.

SECTION A: DEMOGRAPHIC INFORMATION

- A1. City of Practice: ☐ Indore ☐ Jaipur ☐ Lucknow
- A2. Years in Practice: ☐ Less than 5 years ☐ 5 to 15 years ☐ More than 15 years
- A3. Primary Specialisation: ☐ General Practitioner ☐ General Physician (Internal Medicine)
- A4. Average Number of Patient Consultations per Day: _____

SECTION B: MR VISIT FREQUENCY (Circle the number that best represents your experience)

- B1. On average, how many MR visits do you receive per month from all companies combined?
- ☐ 0 ☐ 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 or more
- B2. How many distinct pharmaceutical companies have MRs who visit you at least once a month?
- ☐ 1 to 2 ☐ 3 to 5 ☐ 6 to 10 ☐ More than 10
- B3. How regular and predictable are the visit schedules of MRs who visit you? (1 = Very irregular, 5 = Very regular)

1 2 3 4 5

B4. In the past three months, have the MRs who visit you maintained their scheduled visit frequency?

☐ Yes, consistently ☐ Mostly yes ☐ Sometimes ☐ Rarely ☐ Never

B5. Compared to two years ago, the number of MR visits you receive has: ☐ Increased ☐ Remained the same ☐ Decreased

SECTION C: TERRITORY COVERAGE PERCEPTION (1 = Strongly Disagree, 5 = Strongly Agree)

C1. MRs from most major pharmaceutical companies in my primary prescribing therapeutic areas visit me regularly. 1 2 3 4 5

C2. I feel that I have access to adequate product information from MRs across the categories I prescribe. 1 2 3 4 5

C3. There are therapeutic categories where I prescribe frequently but rarely receive any MR visits. 1 2 3 4 5

C4. The overall coverage of my practice by pharmaceutical field forces is adequate for my clinical needs. 1 2 3 4 5

C5. I would prescribe more branded medicines if more MRs visited me from different companies. 1 2 3 4 5

SECTION D: RELATIONSHIP QUALITY (1 = Strongly Disagree, 5 = Strongly Agree)

D1. The MRs who visit me understand my clinical preferences and prescribing priorities. 1 2 3 4 5

D2. I trust the MRs who visit me regularly to provide accurate and balanced product information. 1 2 3 4 5

D3. The MRs who visit me are reliable and keep their commitments regarding samples and follow-ups. 1 2 3 4 5

D4. I consider at least some of the MRs who visit me to be genuinely helpful to my clinical practice. 1 2 3 4 5

D5. The MRs who visit me treat me with appropriate professional respect. 1 2 3
4 5

D6. The MRs I interact with regularly make an effort to personalise their visits based on my clinical interests. 1 2 3 4 5

D7. Overall, I would describe my relationship with the MRs who visit me as positive and professionally productive. 1 2 3 4 5

SECTION E: DETAILING CONTENT QUALITY (1 = Strongly Disagree, 5 = Strongly Agree)

E1. The product information shared by MRs during detailing visits is clinically relevant to my practice. 1 2 3 4 5

E2. MRs provide scientifically accurate and up-to-date information about the products they detail. 1 2 3 4 5

E3. The clinical evidence shared by MRs (studies, trial data) is useful for my prescribing decisions. 1 2 3 4 5

E4. MRs are able to answer clinical questions about their products satisfactorily. 1
2 3 4 5

E5. The detailing content I receive from MRs has introduced me to treatment options I was not aware of previously. 1 2 3 4 5

E6. Overall, the quality of information shared by MRs during their visits has improved over the past two years. 1 2 3 4 5

SECTION F: PRESCRIPTION INFLUENCE (1 = Strongly Disagree, 5 = Strongly Agree)

F1. MR detailing visits influence my brand choice when multiple clinically equivalent options are available. 1 2 3 4 5

F2. I have switched prescribing from one brand to another following information provided by an MR. 1 2 3 4 5

F3. Regular MR visits from a company increase the likelihood that I will prescribe that company's products. 1 2 3 4 5

F4. I prefer to prescribe brands whose MRs visit me regularly over equivalent brands whose MRs do not. 1 2 3 4 5

F5. Overall, pharmaceutical MR detailing has a meaningful influence on my prescribing decisions. 1 2 3 4 5

Thank you for your time and participation. Your contribution is greatly valued.

ANNEXURE B: SAMPLE DATA EXTRACT

Table A1 Sample Extract from Primary Survey Dataset (First 10 Respondents)

Resp. ID	City	Yrs Practice	MR Visits/Mo	Rel. Quality	Detailing Quality	Territory Coverage	Prescription Influence
R001	Indore	10	3	4.1	3.7	3.9	4.2
R002	Indore	7	2	3.6	3.2	3.4	3.5
R003	Indore	18	3	4.3	3.8	4.0	4.4
R004	Jaipur	5	2	3.1	2.9	3.0	3.1
R005	Jaipur	12	1	2.8	2.6	2.7	2.5
R006	Jaipur	22	2	3.8	3.4	3.5	3.7
R007	Lucknow	9	3	4.0	3.6	3.8	4.0
R008	Lucknow	15	4	4.5	4.1	4.3	4.6
R009	Lucknow	3	2	3.3	3.0	3.2	3.2
R010	Indore	11	3	3.9	3.5	3.7	3.9

Source: Primary survey data. Scores represent mean of construct items on 5-point Likert scale.